Home › Funds › Ghisallo Capital Management LLC › CYTK
Ghisallo Capital Management LLC position in CYTK
CYTOKINETICS INC · Health Care
Ghisallo Capital Management LLC reported holding 170,000 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$11.2M, representing 0.26% of its reported portfolio and ranking #48 among its reported holdings. Ghisallo Capital Management LLC has disclosed CYTK holdings in 3 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Ghisallo Capital Management LLC's CYTK position evolved
Ghisallo Capital Management LLC first disclosed a stake in CYTK in Q2 2024 at 196,000 shares (US$10.6M). The position peaked in Q2 2026 at 170,000 shares, worth US$14.5M. Across 3 filings, Ghisallo Capital Management LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 170,000 shares valued at US$11.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 196.00K | $10.62M | New |
| Q2 2026 | 170.00K | $14.48M | New |
| Q3 2026 | 170.00K | $11.20M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC) is a Health Care company. 40 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$323.0M), Polar Capital Holdings Plc (US$227.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.72M sh · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 4.90M sh · $322.96M · Q3 2026
- Polar Capital Holdings Plc 9.64M sh · $227.69M · Q3 2026
- RTW INVESTMENTS, LP 2.86M sh · $188.63M · Q3 2026
- Frazier Life Sciences Management, L.P. 1.16M sh · $98.81M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.18M sh · $77.79M · Q3 2026
- Integral Health Asset Management, LLC 1.60M sh · $72.50M · Q3 2026
- GW&K Investment Management, LLC 1.02M sh · $67.08M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $64.62M · Q3 2026
- Foresite Capital Management IV, LLC 714.70K sh · $60.88M · Q2 2026
- Melqart Asset Management (UK) Ltd 761.54K sh · $50.19M · Q3 2026
- Affinity Asset Advisors, LLC 750.00K sh · $49.43M · Q3 2026
More on Ghisallo Capital Management LLC
FAQ
How long has Ghisallo Capital Management LLC held CYTK?
Ghisallo Capital Management LLC has disclosed CYTK holdings in 3 of the last 10 reported quarters, going back to Q2 2024.
What is Ghisallo Capital Management LLC's current position in CYTK?
As of Q3 2026, Ghisallo Capital Management LLC holds 170.00K shares of CYTK (CYTOKINETICS INC), valued at $11.20M, representing 0.26% of its reported portfolio and ranking #48.
Has Ghisallo Capital Management LLC been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Ghisallo Capital Management LLC held unchanged its position in CYTK. The position peaked in Q2 2026 at 170.00K shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, Polar Capital Holdings Plc, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.